1.4 The Comprehensive Drug Abuse Prevention and Control Act of 1970

Below you will find pages 27-35 of The Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended through Public Law 115-91, Enacted December 12, 2017
27            TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…      Sec. 202  any comments submitted by the Secretary in response to a notice transmitted pursuant to this paragraph. (1)   A temporary scheduling order issued under paragraph

(1)   shall be vacated upon the issuance of a permanent scheduling order under paragraph (6).

(5)   An order issued under paragraph (1) is not subject to judicial review.

(6)  The Attorney General may, by rule, issue a permanent order adding a drug or other substance to the definition of anabolic steroids if such drug or other substance satisfies the criteria for being considered an anabolic steroid under section 102(41). Such rulemaking may be commenced simultaneously with the issuance of the temporary order issued under paragraph (1).

(j)(1) With respect to a drug referred to in subsection (f), if the Secretary of Health and Human Services recommends that the Attorney General controls the drug in schedule II, III, IV, or V pursuant to subsections (a) and (b), the Attorney General shall, not later than 90 days after the date described in paragraph (2), issue an interim final rule controlling the drug in accordance with such subsections and section 202(b) using the procedures described in paragraph (3).

(2)  The date described in this paragraph shall be the later of—

(A)   the date on which the Attorney General receives the scientific and medical evaluation and the scheduling recommendation from the Secretary of Health and Human Services in accordance with subsection (b); or

(B)   the date on which the Attorney General receives notification from the Secretary of Health and Human Services that  the Secretary has approved an  application  under  section 505(c), 512, or 571 of the Federal Food, Drug, and Cosmetic Act or section 351(a) of the Public Health Service Act, or indexed a drug under section 572 of the Federal Food, Drug, and Cosmetic Act, with respect to the drug described in paragraph (1).

(3)  A rule issued by the Attorney General under paragraph (1) shall become immediately effective as an interim final rule without requiring the Attorney General to demonstrate good cause therefor. The interim final rule shall give interested persons the opportunity to comment and to request a hearing. After the conclusion of such proceedings, the Attorney General shall issue a final rule in accordance with the scheduling criteria of subsections (b), (c), and (d) of this section and section 202(b).

SCHEDULES OF CONTROLLED SUBSTANCES

SEC. 202. ø21 U.S.C. 812¿ (a) There are established five schedules of controlled substances, to be known as schedules I, II, III,    IV, and V. Such schedules shall initially consist of the substances listed in this section. The schedules established by this section shall be updated and republished on a semiannual basis during the two-year period beginning one year after the date of enactment of this title and shall be updated and republished on an annual basis thereafter.

Sec. 202   TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…       28(b)   Except where control is required by United States obligations under an international treaty, convention, or protocol, in effect on the effective date of this part, and except in the case of an immediate precursor, a drug or other substance may not be placed   in any schedule unless the findings required for such schedule are made with respect to such drug or other substance. The findings required for each of the schedules are as follows:

(1)  SCHEDULE I

(A)   The drug or other substance has a high potential for abuse.

(B)   The drug or other substance has no currently accepted medical use in treatment in the United States.

(C)   There is a lack of accepted safety for use of the drug or other substance under medical supervision.

(2)  SCHEDULE II

(A)   The drug or other substance has a high potential for abuse.

(B)   The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.

(C)   Abuse of the drug or other substances may lead to severe psychological or physical dependence.

(3)  SCHEDULE III

(A)  The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.

(B)   The drug or other substance has a currently accepted medical use in treatment in the United States.

(C)   Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.

(4)  SCHEDULE IV

(A)   The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule III.

(B)   The drug or other substance has a currently accepted medical use in treatment in the United States.

(C)   Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.

(5)  SCHEDULE V

(A)   The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.

(B)   The drug or other substance has a currently accepted medical use in treatment in the United States.

(C)   Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.

 

(c) 23 Schedules I, II, III, IV, and V shall, unless and until amended pursuant to section 201, consist of the following drugs or

23 For current placement of substances in the schedules, see part 1308 of title 21, Code of Federal Regulations. Note that the schedules as they appear in section 202 may not show all controlled substances, and in some cases, a substance may actually be on a different schedule than shown in section 202. This is because the Attorney General has rulemaking authority under section 201(a) to add substances to the schedules, to transfer substances from one schedule to another, and to remove substances from the schedules.

29            TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…      Sec. 202other substances, by whatever official name, common or usual name, chemical name, or brand name designated:

SCHEDULE I

(a)    Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1)  Acetylmethadol.

(2)  Allylprodine.

(3)  Alphacetylmethadol. 24

(4)  Alphameprodine.

(5)  Alphamethadol.

(6)  Benzethidine.

(7)  Betacetylmethadol.

(8)  Betameprodine.

(9)  Betamethadol.

(10)  Betaprodine.

(11)  Clonitazene.

(12)  Dextromoramide.

(13)  Dextrorphan.

(14)  Diampromide.

(15)  Diethylthiambutene.

(16)  Dimenoxadol.

(17)  Dimepheptanol.

(18)  Dimethylthiambutene.

(19)  Dioxaphetyl butyrate.

(20)  Dipipanone.

(21)  Ethylmethylthiambutene.

(22)  Etonitazene.

(23)  Etoxeridine.

(24)  Furethidine.

(25)  Hydroxypethidine.

(26)  Ketobemidone.

(27)  Levomoramide.

(28)  Levophenacylmorphan.

(29)  Morpheridine.

(30)  Noracymethadol.

(31)  Norlevorphanol.

(32)  Normethadone.

(33)  Norpipanone.

(34)  Phenadoxone.

(35)  Phenampromide.

(36)  Phenomorphan.

(37)  Phenoperidine.

(38)  Piritramide.

(39)  Proheptazine.

(40)  Properidine.

(41)  Racemoramide.

(42)  Trimeperidine.

24 So in law. Probably should be ‘‘Alphacetylmethadol.’’

 

Sec. 202   TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…       30(b)   Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1)  Acetorphine.

(2)  Acetyldihydrocodeine.

(3)  Benzylmorphine.

(4)  Codeine methylbromide.

(5)  Codeine-N-Oxide.

(6)  Cyprenorphine.

(7)  Desomorphine.

(8)  Dihydromorphine.

(9)  Etorphine.

(10)  Heroin.

(11)  Hydromorphinol.

(12)  Methyldesorphine.

(13)  Methylhydromorphine.

(14)  Morphine methylbromide.

(15)  Morphine methylsulfonate.

(16)  Morphine-N-Oxide.

(17)  Myrophine.

(18)  Nicocodeine.

(19)  Nicomorphine.

(20)  Normorphine.

(21)  Pholcodine.

(22)  Thebacon.

(c)   Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers  is possible within the specific chemical designation:

(1)  3,4-methylenedioxy amphetamine.

(2)  5-methoxy-3,4-methylenedioxy amphetamine.

(3)  3,4,5-trimethoxy amphetamine.

(4)  Bufotenine.

(5)  Diethyltryptamine.

(6)  Dimethyltryptamine.

(7)  4-methyl-2,5-dimethoxy amphetamine.

(8)  Ibogaine.

(9)  Lysergic acid diethylamide.

(10)  Marihuana.

(11)  Mescaline.

(12)  Peyote.

(13)  N-ethyl-3-piperidyl benzilate.

(14)  N-methyl-3-piperidyl benzilate.

(15)  Psilocybin.

(16)  Psilocyn.

(17)  Tetrahydrocannabinols.

(18)  4-methylmethcathinone (Mephedrone).

(19)  3,4-methylenedioxypyrovalerone (MDPV).

(20)  2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E).

(21)   2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D).

 

 

31            TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…      Sec. 202(22)  2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C).

(23)  2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I).

(24)   2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C– T–2).

(25)       2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4).

(26)  2-(2,5-Dimethoxyphenyl)ethanamine (2C–H).

(27)  2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N).

(28)   2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–

P).

(d)(1) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of cannabimimetic agents, or which contains their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

(2)  In paragraph (1):

(A)   The term ‘‘cannabimimetic agents’’ means any substance that is a cannabinoid receptor type 1 (CB1 receptor) agonist as demonstrated by binding studies and functional assays within any of the following structural classes:

(i)   2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alkenyl, whether or not substituted on the cyclohexyl ring to any extent.

(ii)                   3-(1-naphthoyl) indole or 3-(1- naphthylmethane)indole by substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent.

(iii)  3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to any extent.

(iv)   1-(1-naphthylmethylene)indene by substitution of the 3-position of the indene ring, whether or not further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to any extent.

(v)   3-phenylacetylindole or 3-benzoylindole by substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent.

(B)  Such term includes—

(i)                            5-(1,1-dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]ø¿-phenol (CP–47,497);

(ii)                             5-(1,1-dimethyloctyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP– 47,497 C8-homolog);

(iii)      1-pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678);

(iv) 1-butyl-3-(1-naphthoyl)indole (JWH–073);

(v) 1-hexyl-3-(1-naphthoyl)indole (JWH–019);

 

 

Sec. 202   TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…       32(vi)          1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200);

(vii)    1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH– 250);

(viii)  1-pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH– 081);

(ix)      1-pentyl-3-(4-methyl-1-naphthoyl)indole       (JWH– 122);

(x)  1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398);

(xi) 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201);

(xii)        1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM694);

(xiii)      1-pentyl-3-[(4-methoxy)-benzoyl]indole      (SR–19 and RCS–4);

(xiv)        1-cyclohexylethyl-3-(2-

methoxyphenylacetyl)indole (SR–18 and RCS–8); and

(xv)       1-pentyl-3-(2-chlorophenylacetyl)indole       (JWH– 203).

SCHEDULE II

(a)    Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis:

(1)  Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate.

(2)   Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the subs- stances referred to in clause (1), except that these substances shall not include the isoquinoline alkaloids of opium.

(3)  Opium poppy and poppy straw.

(4)   coca 25 leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed; cocaine, its salts, optical and geometric isomers, and salts of isomers; ecgonine, its derivatives, their salts, isomers, and salts of isomers; or any compound, mixture, or preparation which contains any quantity of any of the substances referred to in this paragraph.

(b)   Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1)  Alphaprodine.

(2)  Anileridine.

(3)  Bezitramide.

(4)  Dihydrocodeine.

(5)  Diphenoxylate.

(6)  Fentanyl.

(7)  Isomethadone.

(8)  Levomethorphan.

25 So in law. Probably should be ‘‘Coca’’.

 

33    TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…(9)  Levorphanol.

(10)  Metazocine.

(11)  Methadone.

(12)      Methadone-Intermediate,      4-cyano-2-dimethylamino- 4,4-diphenyl butane.

(13)    Moramide-Intermediate, 2-methyl-3 morpholino-1,1- diphenylpropane-carboxylic acid.

(14)  Pethidine.

(15)   Pethidine-Intermediate-A,          4-cyano-1-methyl-4- phenylpiperidine.

(16)    Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4- carboxylate.

(17)    Pethidine-Intermediate-C,                 1-methyl-4- phenylpiperidine-4-carboxylic acid.

(18)  Phenazocine.

(19)  Piminodine.

(20)  Racemethorphan.

(21)  Racemorphan.

(c)   Unless specifically excepted or unless listed in another schedule, any injectable liquid which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers.

SCHEDULE III

(a) 26 Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(1)  Amphetamine, its salts, optical isomers, and salts of its optical isomers.

(2)  Phenmetrazine and its salts.

(3)   Any substance (except an injectable liquid) which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers.

(4)  Methylphenidate.

(b)   Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1)  Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid.

(2)  Chlorhexadol.

(3)  Glutethimide.

(4)  Lysergic acid.

(5)  Lysergic acid amide.

(6)  Methyprylon.

(7)  Phencyclidine.

(8)  Sulfondiethylmethane.

(9)  Sulfonethylmethane.

(10)  Sulfonmethane.

26 The substances referred to in schedule III(a) have been administratively moved to schedule II.

Sec. 202   TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…       34(c) Nalorphine.

(d)   Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:

(1)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium.

(2)  Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(3)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium.

(4)  Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(5)   Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit,  with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(6)   Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(7)   Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(8)  Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(e)  Anabolic steroids.

SCHEDULE IV

(1)  Barbital.

(2)  Chloral betaine.

(3)  Chloral hydrate.

(4)  Ethchlorvynol.

(5)  Ethinamate.

(6)  Methohexital.

(7)  Meprobamate.

(8)  Methylphenobarbital.

(9)  Paraldehyde.

(10)  Petrichloral.

(11)  Phenobarbital.

SCHEDULE V

Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, which shall include

35            TITLES II AND III OF THE COMPREHENSIVE DRUG ABUSE…      Sec. 204

one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

  • (1) Not more than 200 milligrams of codeine per 100 milliliters or per 100
  • (2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100
  • (3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100
  • (4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage
  • (5) Not more than 100 milligrams of opium per 100 milliliters or per 100

TREATMENT OF CONTROLLED SUBSTANCE ANALOGUES

SEC. 203. ø21 U.S.C. 813¿ A controlled substance analog shall, to the extent intended for human consumption,  be treated, for the purposes of any Federal law as a controlled substance in schedule I.

REMOVAL OF EXEMPTION OF CERTAIN DRUGS

SEC. 204. ø21 U.S.C. 814¿ (a) REMOVAL OF EXEMPTION.—The

Attorney General shall by regulation remove from exemption under section 102(39)(A)(iv) a drug or group of drugs that the Attorney General finds is being diverted to obtain a listed chemical for use in the illicit production of a controlled substance.

  • (b) FACTORS TO BE CONSIDERED.—In removing a drug or group of drugs from exemption under subsection (a), the Attorney General shall consider, with respect to a drug or group of drugs that is proposed to be removed from exemption—
    • (1) the scope, duration, and significance of the diversion;
    • (2) whether the drug or group of drugs is formulated in such a way that it cannot be easily used in the illicit production of a controlled substance; and
    • (3) whether the listed chemical can be readily recovered from the drug or group of
  • (c) SPECIFICITY OF DESIGNATION.—The Attorney General shall limit the designation of a drug or a group of drugs removed from exemption under subsection (a) to the most particularly identifiable type of drug or group of drugs for which evidence of diversion exists unless there is evidence, based on the pattern of  diversion  and  other relevant factors, that the diversion will not be limited to that particular drug or group of
  • (d) REINSTATEMENT OF EXEMPTION WITH RESPECT TO PAR-

TICULAR DRUG PRODUCTS.—

  • (1) REINSTATEMENT.—On application by a manufacturer of a particular drug product that has been removed from exemption under subsection (a), the Attorney General shall by regulation reinstate the exemption with respect to that particular drug product if the Attorney General determines that the particular drug product is manufactured and distributed in a manner that prevents

License

Icon for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License

Drugs, Health & Behavior by Jacqueline Schwab is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, except where otherwise noted.

Share This Book